• DPPH Antioxidant Screening Workflow

  2026-08-24

  Use DPPH to rank antioxidant capacity rapidly across small molecules, botanical extracts, and cultivation samples. Its plate-compatible color change is especially useful when paired with LC-MS/MS and orthogonal assays to distinguish promising hits from assay artifacts.

• Bestatin (Ubenimex) in Protease Research

  2026-08-23

  Bestatin (Ubenimex) is a selective aminopeptidase probe for connecting enzyme activity with cell behavior, MDR biology, apoptosis assays, and fibrin-based angiogenesis models. APExBIO supplies a research-use reagent suited to workflows that require careful dose selection, orthogonal controls, and matrix-aware interpretation.

• PBS (Phosphate-Buffered Saline): Practical Lab Guide

  2026-08-22

  PBS (Phosphate-Buffered Saline), SKU K2818, provides a sterile, isotonic buffer for routine cell washing, reagent dilution, and compatible in vitro workflows requiring controlled pH. It is for scientific research use only and should not be used for diagnostic, medical, clinical, or in vivo applications.

• Remdesivir (GS-5734): A Polymerase Assay Roadmap

  2026-08-21

  Remdesivir (GS-5734) is examined here through an assay-centered lens, connecting its coronavirus and filovirus activity with new structural insights into the Nipah virus polymerase complex. The article clarifies what polymerase architecture can—and cannot—predict for antiviral research.

• Tamoxifen as a Temporal Control Tool in Biology

  2026-08-20

  Tamoxifen is a selective estrogen receptor modulator with applications extending from breast cancer research to inducible genetics. This article explains how its time-dependent biology can improve causal assay design, using recurrent airway inflammation as a model for experimental reasoning.

• DPPH Antioxidant Screening: From Signal to Strategy

  2026-08-20

  DPPH converts radical-scavenging chemistry into a practical development signal. This thought-leadership guide explains how to use DPPH (2,2-Diphenyl-1-Picrylhydrazyl) Radical in extract profiling, high-throughput screening, and translational decision-making, using new Taihangia rupestris evidence to show why assay context and orthogonal validation matter.

• Actinomycin D: Designing Causal RNA Decay Assays

  2026-08-19

  Actinomycin D and ActD are more than broad transcriptional inhibitors: they are perturbational tools for separating RNA synthesis from post-transcriptional decay. This guide develops an assay-design framework grounded in AML WTAP–m6A research, with practical controls, interpretation strategies, and handling guidance.

• tRF16–ALKBH5 Drives Osteoarthritis Progression

  2026-08-19

  The reference study identifies tRF16 as an overexpressed tRNA-derived fragment that links ALKBH5, NFKBIA mRNA stability, and NF-κB activation in osteoarthritis. Its combined human, animal, and chondrocyte experiments provide a mechanistic framework for understanding how post-transcriptional RNA regulation can promote cartilage degeneration and inflammation.

• circ_0000235, MCT4, and Glycolysis in Bladder Cancer

  2026-08-18

  The reference study identifies circ_0000235 as an upstream regulator of MCT4-driven glycolysis in bladder cancer through sequestration of miR-330-5p. Its integrated molecular, metabolic, cellular, and animal evidence links this competing endogenous RNA axis to tumor growth and migration, while suggesting experimental opportunities for studying transcriptional stress and RNA stability alongside cancer metabolism.

• Trichostatin A (TSA) in Cancer Research

  2026-08-18

  Trichostatin A (TSA) gives researchers a reversible way to connect histone acetylation with differentiation, proliferation, and cell-cycle phenotypes. This practical guide shows how to deploy TSA in cancer research while using mitochondrial calcium and GPX4 findings as a disciplined, hypothesis-generating bridge rather than an assumed mechanism.

• A1 and CXCR4 Targeting in Colorectal Cancer

  2026-08-17

  Khorramdelazad et al. evaluated A1, a fluorinated CXCR4 inhibitor, through molecular simulation, CT-26 cell assays, and a syngeneic colorectal cancer model. A1 showed more favorable simulated CXCR4 binding than AMD3100 and produced stronger antitumor, anti-migratory, and tumor-microenvironment effects in the reported preclinical systems.

• Cytarabine (AraC): Mechanism and Research Use

  2026-08-17

  Cytarabine, also called AraC, is a deoxycytidine-related nucleoside analog that inhibits DNA synthesis after intracellular phosphorylation. Its value in leukemia research comes from the direct connection between dCK activation, polymerase inhibition, apoptosis, and measurable resistance phenotypes.

• DEV VP26 Maps an Actin–Myosin II Host Network

  2026-08-16

  This study combines VP26 affinity purification, proteomics, interaction validation, and functional perturbation to identify the host actin–myosin II network as a determinant of duck enteritis virus proliferation. Its findings nominate MYH9 as an important host factor and provide a framework for testing how cytoskeletal machinery supports herpesvirus infection.

• Mc-Val-Cit-PABC-PNP ADC Linker Guide

  2026-08-15

  Mc-Val-Cit-PABC-PNP is a cathepsin-cleavable peptide linker for research workflows involving antibody-drug conjugate synthesis and lysosomal payload release. It is supplied as a solid, dissolves in DMSO, and should not be treated as a water- or ethanol-compatible reagent or as a diagnostic, therapeutic, or medical product.

• H4K12 Lactylation Drives TNBC via SLFN5 Loss

  2026-08-14

  The reference study identifies histone H4K12 lactylation as a metabolic-to-epigenetic mechanism that promotes triple-negative breast cancer progression by suppressing SLFN5. Its combination of tissue analysis, metabolic perturbation, chromatin profiling, reporter assays, and rescue experiments provides a practical framework for studying lactate-dependent gene regulation in cancer metabolism research.

7886 records 1/526 page Next 12345 下5页 Last page